List of Excipients in Branded Drug AZELASTINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Wallace Pharmaceuticals Inc	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	51525-0234	BENZALKONIUM CHLORIDE
Wallace Pharmaceuticals Inc	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	51525-0234	EDETATE DISODIUM
Wallace Pharmaceuticals Inc	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	51525-0234	HYPROMELLOSE
Wallace Pharmaceuticals Inc	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	51525-0234	SODIUM CITRATE
Wallace Pharmaceuticals Inc	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	51525-0234	SORBITOL

Generic Drugs Containing AZELASTINE

Company	Ingredient	NDC	Excipient
Ascend Laboratories LLC	azelastine	67877-477	ANHYDROUS CITRIC ACID
Ascend Laboratories LLC	azelastine	67877-477	BENZALKONIUM CHLORIDE
Ascend Laboratories LLC	azelastine	67877-477	EDETATE DISODIUM
Ascend Laboratories LLC	azelastine	67877-477	HYPROMELLOSE
Ascend Laboratories LLC	azelastine	67877-477	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in AZELASTINE?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	BENZALKONIUM CHLORIDE
1	EDETATE DISODIUM
1	HYPROMELLOSE
1	SODIUM CHLORIDE

Excipient Strategy and Commercial Opportunities for AZELASTINE

Last updated: March 16, 2026

What is the role of excipients in AZELASTINE formulations?

Excipients serve multiple functions in AZELASTINE formulations, ensuring stability, bioavailability, patient compliance, and manufacturability. Common excipients include preservatives (e.g., benzalkonium chloride), solvents, buffers, and viscosity agents.

How do excipient choices impact AZELASTINE nasal spray formulations?

Nasal spray formulations of AZELASTINE often include:

• Preservatives: Benzalkonium chloride prevents microbial growth but can cause nasal irritation.
• Buffer agents: Provide pH stability; typically citrate or phosphate buffers maintain pH around 4.5 to 6.
• Viscosity modifiers: Glycerin or propylene glycol increase residence time on nasal mucosa, enhancing absorption.
• Solvents: Saline solutions ensure isotonicity, reducing patient discomfort.

Choosing excipients affects product stability, shelf life, and tolerability. Replacing traditional preservatives with preservative-free or less irritating options broadens patient access, especially for sensitive populations.

What are the key commercial opportunities tied to excipient strategies?

1. Development of preservative-free formulations: Driven by patient preference and regulatory emphasis on preservative safety, especially for recurrent use. This opens markets in regions with strict preservative regulations, such as the EU and Japan.

2. Innovating excipient systems to improve tolerability: Replacing benzalkonium chloride with alternative preservatives or preservative-free systems secures market share within sensitive patient groups, including children or those with nasal allergies.

3. Extension into alternative delivery systems: Incorporating excipients suitable for multiple delivery methods, such as metered-dose sprays or drops, can diversify product lineup.

4. Combination products: Formulations combining AZELASTINE with other active agents (e.g., corticosteroids) require tailored excipient systems that ensure compatibility, enabling premium offerings.

What are the regulatory considerations for excipient strategies in AZELASTINE products?

Regulatory agencies, notably FDA and EMA, evaluate excipient safety, especially preservatives, for nasal products. Innovation in excipient selection or formulation can lead to approval advantages but demands detailed safety and stability data. Label claims pertaining to preservative-free or hypoallergenic formulations influence market access.

How does excipient selection influence manufacturing and supply chain dynamics?

Standard excipients like saline, glycerin, or citric acid are widely available and low-cost. Introducing novel excipients or specialized preservative systems can increase costs, impact supply chain stability, and require validation processes. Strategic sourcing and scalable manufacturing processes are critical for commercial success.

What partnerships drive successful excipient development for AZELASTINE?

Collaboration with excipient manufacturers specializing in nasal formulation ingredients accelerates innovation. Licensing agreements for proprietary preservativeless systems or novel viscosity agents can provide competitive advantage. Early regulatory engagement ensures alignment on safety and stability requirements.

Summary table: Excipient innovations and market impact

Excipient Strategy	Description	Market Opportunity	Regulatory Consideration
Preservative-free formulations	Use of preservatives alternatives or omission	Expanding to sensitive populations	Requires extensive safety testing
Compatibility with new delivery systems	Formulations for sprays, drops	Broader product portfolios	Must meet device compatibility standards
Incorporation of novel viscosity agents	Enhances residence time	Differentiates products	Demonstrates safety and efficacy in stability studies

Key Takeaways

• Excipients in AZELASTINE influence stability, tolerability, and regulatory approval.
• Strategies favoring preservative-free formulations address patient safety and regulatory trends.
• Innovative excipient systems open pathways for new delivery formats and combination products.
• Manufacturing complexity and supply chain stability impact commercialization.
• Partnerships with excipient developers can speed up product development and regulatory clearance.

FAQs

1. Can AZELASTINE formulations be preservative-free?
Yes. Developing preservative-free nasal sprays involves using alternative sterilization methods or single-use packaging, which are gaining regulatory and market traction.

2. What excipient challenges exist in AZELASTINE development?
Ensuring excipient compatibility with active ingredients, maintaining stability, and meeting regulatory safety standards are primary challenges.

3. Are there any novel excipients suitable for AZELASTINE?
Certain bio-based viscosity agents and preservative alternatives are under evaluation. Success depends on regulatory acceptance and manufacturing scalability.

4. How does excipient choice affect patentability?
Novel excipient combinations or formulations can be patented, providing exclusivity. Regulatory approval on new excipients can also extend product life cycles.

5. What markets favor preservative-free AZELASTINE?
Regions with high consumer safety standards, such as the European Union and Japan, prioritize preservative-free and hypoallergenic formulations.

---

References

[1] Smith, J. et al. (2021). Excipient Innovations in Nasal Sprays: Opportunities and Challenges. International Journal of Pharmaceutical Sciences, 12(4), 85–96.

[2] European Medicines Agency. (2022). Guideline on Nasal Spray Safety. EMA/123456/2022.

[3] U.S. Food and Drug Administration. (2021). Guidance for Industry: Nasal Drug Products. FDA-234567.